bay 73-6691 bay 73-6691 bay 73-6691 is a drug developed by bayer for the treatment of alzheimer's disease. it was the first compound developed that acts as a phosphodiesterase inhibitor selective for the pde9a subtype. the pde9a enzyme is expressed primarily in the brain, with high concentrations in the cerebellum, neocortex, striatum, and hippocampus, and acts to limit the cgmp-mediated signal transduction which occurs following glutamate binding to nmda receptors. consequently, selective pde9a inhibitors were predicted to prolong intracellular responses to glutamate and enhance glutamate signalling, and since this process is known to be involved in learning and memory, pde9a inhibitors should have a nootropic effect and may be useful in the treatment of alzheimer's. bay 73-6691clinical dataatc codenoneidentifiers iupac name 1-(2-chlorophenyl)-6--1,5-dihydro-4h-pyrazolopyrimidine-4-one cas number794568-92-6 ypubchem cid16078952chemspider21171546 yunii80ztv3intwchemblchembl1513993 necha infocard100.150.853 chemical and physical dataformulac15h12clf3n4omolar mass356.73 g·mol−13d model (jsmol)interactive image smiles c(cc1=nc(=o)c2=cnn(c2=n1)c3=cc=cc=c3cl)c(f)(f)f inchi inchi=1s/c15h12clf3n4o/c1-8(15(17,18)19)6-12-21-13-9(14(24)22-12)7-20-23(13)11-5-3-2-4-10(11)16/h2-5,7-8h,6h2,1h3,(h,21,22,24)/t8-/m1/s1 ykey:ffpxpxoafqcnbs-mrvpvssysa-n y ny (what is this?) (verify) animal studies have confirmed these expectations, and bay 73-6691 has been shown to improve learning and memory in rats. as the first selective pde9a inhibitor to be developed, it is also widely used in research into the function of this enzyme subtype. however pre-clinical research is at an early stage and it is not yet known whether bay 73-6691 will prove suitable to progress to human trials, or if it will remain merely a laboratory research tool.